{"type":"trials","record":{"id":33580,"source_id":"clinicaltrials-gov","external_id":"NCT05284604","title":"Mesenchymal Stem Cells for Age-Related Frailty","brief_summary":"Frailty is a health state related to the aging process in which multiple body systems gradually lose their built-in reserves. It is a medical condition of reduced function in older adults which is associated with increased risks of adverse outcomes such as falls, disability, admission to hospital, or need for long-term care. Currently, there is no specific medical treatment of frailty. Mesenchymal stem cells (MSCs) are undifferentiated cells that self-replicated, and some may change into a particular cell type. These cells go to areas of injury due to signals released by injured cells. Upon reaching, the target tissue, MSCs repair injury by releasing growth factors and immune modulators to assist in the body's repair process. This initial study will assess the practicability of using MSCs for age-related frailty and provide information for planning a future full study of MSCs for maximizing Veteran's functional independence.","overall_status":"Withdrawn","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"VA Office of Research and Development","enrollment":0,"countries":["United States"],"start_date":"2023-01-31","completion_date":"2023-01-31","last_update_date":"2023-02-06","source_url":"https://clinicaltrials.gov/study/NCT05284604","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:20:11.10691+00:00","last_seen_at":"2026-09-25T06:20:19.667+00:00","metadata":{"sex":"ALL","acronym":"MESCAFY","age_range":"65 Years to 85 Years","comparator":"Group 3","organization":"VA Office of Research and Development","interventions":["Mesenchymal Stem Cells (MSCs)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Adherence — Through study completion at 6 months","Recruitment — Through study completion at 6 months","Modified Physical Performance Test — Change from baseline to 6 months","6-Minute Walk Test — Change from baseline to 6 months"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Frailty","Mesenchymal Stem Cells (MSCs)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: stem cell.","quality_checked_at":"2026-09-25T06:20:27.00315+00:00","duplicate_cluster_key":"id:nct05284604","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-01-31 to 2023-01-31","comparator":"Group 3","confidence":"structured-source","population":"ALL · 65 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:19.728Z","intervention":["Mesenchymal Stem Cells (MSCs)"],"participants":0,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Adherence — Through study completion at 6 months","Recruitment — Through study completion at 6 months","Modified Physical Performance Test — Change from baseline to 6 months","6-Minute Walk Test — Change from baseline to 6 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"stem-cells","is_published":true,"match_reasons":["Title contains controlled term: stem cell.","Abstract contains controlled term: stem cell.","Source terminology contains: stem cell.","Title supplies longevity context: frailty, frail.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Stem cells","slug":"stem-cells"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/33580","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}